Skip to main content

Advertisement

Articles

Page 1 of 6

  1. Considerable progress has been made in cancer therapeutics recently with targeted strategies that are efficacious and less toxic. Immunotherapy and chimeric antigen receptor (CAR) T-cells are increasingly bein...

    Authors: Muhammad Bilal Abid, Nirav N. Shah, Theresa C. Maatman and Parameswaran N. Hari

    Citation: Experimental Hematology & Oncology 2019 8:31

    Content type: Review

    Published on:

  2. Medulloblastoma is the most frequently occurring malignant brain tumor in children. Current treatment strategies for medulloblastoma include aggressive surgery, cranio-spinal irradiation and adjuvant chemother...

    Authors: Shanshan Zhang, Zhaojian Gong, Peter O. Oladimeji, Duane G. Currier, Qipan Deng, Ming Liu, Taosheng Chen and Yong Li

    Citation: Experimental Hematology & Oncology 2019 8:30

    Content type: Research

    Published on:

  3. DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive geno...

    Authors: Ming Yi, Bing Dong, Shuang Qin, Qian Chu, Kongming Wu and Suxia Luo

    Citation: Experimental Hematology & Oncology 2019 8:29

    Content type: Review

    Published on:

  4. Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine k...

    Authors: Juanjuan Zhao, Yongping Song and Delong Liu

    Citation: Experimental Hematology & Oncology 2019 8:28

    Content type: Review

    Published on:

  5. The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy. However, this treatment modality c...

    Authors: Bill X. Wu, No-Joon Song, Brian P. Riesenberg and Zihai Li

    Citation: Experimental Hematology & Oncology 2019 8:27

    Content type: Editorial

    Published on:

  6. Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However...

    Authors: Kongju Wu, Ming Yi, Shuang Qin, Qian Chu, Xinhua Zheng and Kongming Wu

    Citation: Experimental Hematology & Oncology 2019 8:26

    Content type: Review

    Published on:

  7. The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of a...

    Authors: Julie H. Selim, Shagufta Shaheen, Wei-Chun Sheu and Chung-Tsen Hsueh

    Citation: Experimental Hematology & Oncology 2019 8:25

    Content type: Review

    Published on:

  8. Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L79...

    Authors: Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw and Rebecca J. Nagy

    Citation: Experimental Hematology & Oncology 2019 8:24

    Content type: Rapid communication

    Published on:

  9. Microvesicles as a new device of cell–cell communication are potentially able to induce some phenotypes and genotypes of an origin cell in a target cell. We evaluate the role of leukemia microvesicles on the l...

    Authors: Farnaz Razmkhah, Sorayya Ghasemi, Masoud Soleimani and Sedigheh Amini Kafi-abad

    Citation: Experimental Hematology & Oncology 2019 8:23

    Content type: Letter to the Editor

    Published on:

  10. The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment...

    Authors: Daniele Santini, Fabrizio Citarella, Bruno Vincenzi, Marco Russano, Giuseppe Tonini and Marco Stellato

    Citation: Experimental Hematology & Oncology 2019 8:22

    Content type: Letter to the Editor

    Published on:

  11. The word of hemoglobinopathy is described for an array of disorders that affecting hemoglobin (Hb) functions. Hb is a molecule with 68 kDa molecular weight, serving as oxygen carrying metalloprotein. Hemoglobi...

    Authors: Zahra Mousavi, Zinat Yazdani, Alireza Moradabadi, Fatemeh Hoseinpourkasgari and Gholamhossein Hassanshahi

    Citation: Experimental Hematology & Oncology 2019 8:21

    Content type: Review

    Published on:

  12. Programmed death-1 (PD-1) inhibitors are among the immunotherapies that have revolutionized our approach to treating several cancers. These novel agents act by blocking PD-1 receptor/PD-1 ligand interactions t...

    Authors: Hoda Z. Pourhassan, David Tryon, Brett Schaeffer, Hamid Mirshahidi and John Wong

    Citation: Experimental Hematology & Oncology 2019 8:20

    Content type: Case report

    Published on:

  14. The human concentrative nucleoside transporter 1 (hCNT1) a product of the SLC28A1 gene is one of the three concentrative nucleoside transporters, with a substrate specificity for physiological pyrimidine nucleosi...

    Authors: Chunmei Wang and John K. Buolamwini

    Citation: Experimental Hematology & Oncology 2019 8:18

    Content type: Short report

    Published on:

  15. Large clonal populations of cells bearing PIG-A mutations are the sine qua non of PNH, but the PIG-A mutation itself is insufficient for clonal expansion. The association between PNH and aplastic anemia supports ...

    Authors: Camille Lobry, Ashish Bains, Leah B. Zamechek, Sherif Ibrahim, Iannis Aifantis and David J. Araten

    Citation: Experimental Hematology & Oncology 2019 8:17

    Content type: Research

    Published on:

  16. Therapy for chronic myeloid leukemia (CLL) is going through a major paradigm shift. Combination chemoimmunotherapy regimens have been the frontline therapies for CLL, whereas chlorambucil remained the standard...

    Authors: Delong Liu and Juanjuan Zhao

    Citation: Experimental Hematology & Oncology 2019 8:15

    Content type: Review

    Published on:

  17. The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antib...

    Authors: Alexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman and Sara Ek

    Citation: Experimental Hematology & Oncology 2019 8:16

    Content type: Short report

    Published on:

  18. Monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) (e.g., ipilimumab [IPI]) and the programmed cell death-1 (PD1) receptor (e.g., nivolumab [NIVO]) represent significant br...

    Authors: Ravi Potluri, Sandip Ranjan, Hitesh Bhandari, Helen Johnson, Andriy Moshyk and Srividya Kotapati

    Citation: Experimental Hematology & Oncology 2019 8:14

    Content type: Research

    Published on:

  20. Many cases of acute lymphoblastic leukemia (ALL) carry visible acquired chromosomal changes of pathogenetic, diagnostic, and prognostic importance. Nevertheless, from one-fourth to half of newly diagnosed ALL ...

    Authors: Ioannis Panagopoulos, Marta Brunetti, Margrethe Stoltenberg, Rønnaug A. U. Strandabø, Julie Staurseth, Kristin Andersen, Ilyá Kostolomov, Tarjei S. Hveem, Susanne Lorenz, Tove Anita Nystad, Trond Flægstad, Francesca Micci and Sverre Heim

    Citation: Experimental Hematology & Oncology 2019 8:12

    Content type: Case report

    Published on:

  21. Hepatoblastoma is the most common hepatic malignancy in children, accounting for approximately 80% of all childhood liver tumors. KRAS and NRAS, members of the RAS gene family, are closely linked to tumorigenesis...

    Authors: Tianyou Yang, Yang Wen, Jiahao Li, Tianbao Tan, Jiliang Yang, Jing Pan, Chao Hu, Yuxiao Yao, Jiao Zhang, Yijuan Xin, Suhong Li, Huimin Xia, Jing He and Yan Zou

    Citation: Experimental Hematology & Oncology 2019 8:11

    Content type: Research

    Published on:

  22. Myeloproliferative neoplasms (MPN) are heterogeneous diseases that classified by the presence of Philadelphia chromosome into Philadelphia chromosome negative (Ph-neg) and positive (Ph-pos) myeloproliferative ...

    Authors: Alireza Moradabadi, Alireza Farsinejad, Behzad Khansarinejad and Ahamd Fatemi

    Citation: Experimental Hematology & Oncology 2019 8:10

    Content type: Research

    Published on:

  23. Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effecti...

    Authors: Stefanie Jilg, Richard T. Hauch, Johanna Kauschinger, Lars Buschhorn, Timo O. Odinius, Veronika Dill, Catharina Müller-Thomas, Tobias Herold, Peter M. Prodinger, Burkhard Schmidt, Dirk Hempel, Florian Bassermann, Christian Peschel, Katharina S. Götze, Ulrike Höckendorf, Torsten Haferlach…

    Citation: Experimental Hematology & Oncology 2019 8:9

    Content type: Rapid communication

    Published on:

  24. Immune checkpoint inhibitors have radically changed the landscape of anti-tumor therapies in several malignancies. However the adverse events associated with immune checkpoint blockade in combination with othe...

    Authors: Julie Charles, Diane Giovannini, Nicolas Terzi, Carole Schwebel, Nathalie Sturm, Dominique Masson, Marie-Thérèse Leccia, Jean-Yves Cahn, Olivier Manches, Claude-Eric Bulabois and Laurence Chaperot

    Citation: Experimental Hematology & Oncology 2019 8:8

    Content type: Case report

    Published on:

  25. Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality.

    Authors: Mattias Carlsten, Martin Jädersten, Anna Hellström, Karin Littmann, Christopher M. Melén, Henna Riikka Junlén, Kristina Sonnevi, Per Ljungman, Bo Björkstrand and Björn Engelbrekt Wahlin

    Citation: Experimental Hematology & Oncology 2019 8:7

    Content type: Research

    Published on:

  26. Thyroid dysfunction has not been previously reported in clinical trials of selective fibroblast growth factor receptor (FGFR) inhibitors including AZD4547. Herein, we report a case of worsening hypothyroidism ...

    Authors: Jeffrey Ahn, Justin Moyers, John Wong and Chung-Tsen Hsueh

    Citation: Experimental Hematology & Oncology 2019 8:6

    Content type: Case report

    Published on:

  27. Small cell lung cancer which constitutes about 15% of lung cancers is pathobiologically and clinically distinct from non small cell cancer. Histologically it is characterized by small cells with scant cytoplas...

    Authors: Vaibhav Verma, Geeti Sharma and Abhijai Singh

    Citation: Experimental Hematology & Oncology 2019 8:5

    Content type: Review

    Published on:

  28. The development of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) is well recognised in multiple myeloma (MM). SIADH, due to either MM or Bortezomib can be hazardous as se...

    Authors: N. O’Connor-Byrne, S. Glavey, R. Tudor, P. Murphy, C. J. Thompson and J. Quinn

    Citation: Experimental Hematology & Oncology 2019 8:4

    Content type: Case report

    Published on:

  29. Cytogenetic abnormalities and mutated genes indicate the role of consolidation therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute myeloid leukemia (AML). In this study, we con...

    Authors: Pimjai Niparuck, Nittaya Limsuwanachot, Sulada Pukiat, Pichika Chantrathammachart, Budsaba Rerkamnuaychoke, Sutada Magmuang, Sithakom Phusanti, Kochawan Boonyawat, Teeraya Puavilai, Pantep Angchaisuksiri, Artit Ungkanont and Suporn Chuncharunee

    Citation: Experimental Hematology & Oncology 2019 8:3

    Content type: Research

    Published on:

  30. Mantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of 2.5–6% non-Hodgkin’s lymphomas. The complexity of its clinical presentations (nodular pattern, diffuse pattern...

    Authors: Abdullah Ladha, Jianzhi Zhao, Elliot M. Epner and Jeffrey J. Pu

    Citation: Experimental Hematology & Oncology 2019 8:2

    Content type: Review

    Published on:

  31. Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT.

    Authors: Yun Fan, Andrew S. Artz, Koen van Besien, Wendy Stock, Richard A. Larson, Olatoyosi Odenike, Lucy A. Godley, Justin Kline, John M. Cunningham, James L. LaBelle, Michael R. Bishop and Hongtao Liu

    Citation: Experimental Hematology & Oncology 2019 8:1

    Content type: Research

    Published on:

  32. Senescence, a state of permanent cell cycle arrest, can be induced by DNA damage. This process, which was initially described in fibroblasts, is now recognized to occur in stem cells. It has been well characte...

    Authors: Stephen Capone, Anthony R. Colombo, Benjamin K. Johnson, Tim J. Triche Jr. and Giridharan Ramsingh

    Citation: Experimental Hematology & Oncology 2018 7:32

    Content type: Research

    Published on:

  33. The evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and p...

    Authors: Yee Yee Yap, Kian Boon Law, Jameela Sathar, Ngee Siang Lau, Ai Sim Goh, Teng Keat Chew, Soo Min Lim, Padmini Menon, Yong Khee Guan, Azlan Bin Husin, Lily Lee Lee Wong, Lee Ping Chew, Sinari Salleh, Kim Yen Goh, Kin Wah Leong, Sen Mui Tan…

    Citation: Experimental Hematology & Oncology 2018 7:31

    Content type: Research

    Published on:

  34. Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases...

    Authors: Hanxiao Xu, Ying Jiao, Shuang Qin, Weiheng Zhao, Qian Chu and Kongming Wu

    Citation: Experimental Hematology & Oncology 2018 7:30

    Content type: Review

    Published on:

  35. Refinement of risk-based treatment stratification by minimal residual disease (MRD) at different time points has improved outcomes of childhood acute lymphoblastic leukemia (ALL). In this prospective study we ...

    Authors: Wasil Jastaniah, Naglla Elimam, Khalid Abdalla, Aeshah A. AlAzmi, Aml M. Elgaml, Ahmad Alkassar, Mustafa Daghistani and Sami Felimban

    Citation: Experimental Hematology & Oncology 2018 7:29

    Content type: Research

    Published on:

  36. Immune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing o...

    Authors: Ming Yi, Shuang Qin, Weiheng Zhao, Shengnan Yu, Qian Chu and Kongming Wu

    Citation: Experimental Hematology & Oncology 2018 7:28

    Content type: Review

    Published on:

  37. The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells. Because mobilized CD34+ cells are critical for stem cell...

    Authors: Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga and Raymond L. Comenzo

    Citation: Experimental Hematology & Oncology 2018 7:27

    Content type: Research

    Published on:

  38. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression ...

    Authors: Kamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, Marina Konopleva, Michael Kroll, Madeleine Nguyen-Cao, Marisa Hornbaker, Courtney D. DiNardo, Tapan Kadia, Jeffrey Jorgensen, Michael Andreeff, Shimin Hu and Christopher B. Benton

    Citation: Experimental Hematology & Oncology 2018 7:26

    Content type: Case report

    Published on:

  39. Immunotherapeutic protocols have focused on identification of stimuli that induce effective anti-leukemic immune responses. One potent immune stimulus is the encounter with allogeneic cells. Our group previous...

    Authors: Alejandro Pando, John L. Reagan, Martha Nevola and Loren D. Fast

    Citation: Experimental Hematology & Oncology 2018 7:25

    Content type: Short report

    Published on:

  40. Estrogen is a steroid hormone that has critical roles in reproductive development, bone homeostasis, cardiovascular remodeling and brain functions. However, estrogen also promotes mammary, ovarian and endometr...

    Authors: Hui Hua, Hongying Zhang, Qingbin Kong and Yangfu Jiang

    Citation: Experimental Hematology & Oncology 2018 7:24

    Content type: Review

    Published on:

  41. Heparin-induced antibodies (HIA) are responsible for causing heparin-induced thrombocytopenia and thrombosis. Research has shown that the temporality of heparin-induced antibodies does not follow the classic i...

    Authors: Satish Maharaj, Simone Chang, Karan Seegobin, James Morales, Agnes Aysola, Fauzia Rana and Marwan Shaikh

    Citation: Experimental Hematology & Oncology 2018 7:23

    Content type: Research

    Published on:

  42. Chemotherapy-induced neutropenia is a common result of myelosuppressive chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the duration of neutropenia as well as the depth of ...

    Authors: Kalpna Desai, Priya Misra, Sanyukta Kher and Nirmesh Shah

    Citation: Experimental Hematology & Oncology 2018 7:22

    Content type: Research

    Published on:

  43. Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-mont...

    Authors: Elena V. Poddubskaya, Madina P. Baranova, Daria O. Allina, Philipp Y. Smirnov, Eugene A. Albert, Alexey P. Kirilchev, Alexey A. Aleshin, Marina I. Sekacheva and Maria V. Suntsova

    Citation: Experimental Hematology & Oncology 2018 7:21

    Content type: Case report

    Published on:

  44. Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 receptor and is typically used in the setting of metastatic breast cancer. Both ERBB2 (HER2) and ERBB3 (HER3) belong to the same family of receptor...

    Authors: John D. Strickley, Aaron C. Spalding, M. Tye Haeberle, Timothy Brown, Don A. Stevens and Jae Jung

    Citation: Experimental Hematology & Oncology 2018 7:20

    Content type: Case report

    Published on:

  45. The positive association of multiple myeloma (MM) risk with HLA-C loci C*07:02 g and C*02:02 g, and the negative association of that with C*05:01 g were statistically significant in Whites have recently been r...

    Authors: Xiaojing Wang, Gang An, Jiying Wang, Yan Zhang, Qinghua Li, Hui wei, Lugui Qiu and Kun Ru

    Citation: Experimental Hematology & Oncology 2018 7:19

    Content type: Research

    Published on:

  46. The objective of this randomized placebo-controlled study was to investigate the efficacy and safety of clarithromycin in combination with bortezomib–cyclophosphamide–dexamethasone (VCD) in patients with newly...

    Authors: Henrik Gregersen, Trung Do, Ida Bruun Kristensen, Ulf Christian Frølund, Niels Frost Andersen, Lene Kongsgaard Nielsen, Christen Lykkegaard Andersen, Tobias Wirenfeldt Klausen, Annette Juul Vangsted and Niels Abildgaard

    Citation: Experimental Hematology & Oncology 2018 7:18

    Content type: Research

    Published on:

  47. Prognosis is very poor for advanced HCC patients partially due to lack of effective systemic treatment. Sorafenib was the only approved agent for advanced HCC since 2007 until recent breakthroughs. In this art...

    Authors: Sowmini Medavaram and Yue Zhang

    Citation: Experimental Hematology & Oncology 2018 7:17

    Content type: Review

    Published on:

  48. Patients with polycythemia vera (PV) have a higher mortality risk compared with the general population, primarily driven by cardiovascular disease, thrombotic events (TEs), and hematologic transformations. The...

    Authors: Dilan Paranagama, Philomena Colucci, Kristin A. Evans, Machaon Bonafede and Shreekant Parasuraman

    Citation: Experimental Hematology & Oncology 2018 7:16

    Content type: Research

    Published on:

  49. Bullous hemorrhagic dermatosis (BHD) is a systemic side-effect of low molecular weight heparin, characterized by multiple intra-epidermal hemorrhages distant from the site of injection. There have been several...

    Authors: Armand Russo, Susanna Curtis, Raisa Balbuena-Merle, Roxanne Wadia, Ellice Wong and Herta H. Chao

    Citation: Experimental Hematology & Oncology 2018 7:15

    Content type: Review

    Published on:

  50. Bone marrow transplant-associated thrombotic microangiopathy (TA-TMA) is a relatively frequent but under-recognized and under-treated hematopoietic stem cell transplant (HSCT) complication that leads to signif...

    Authors: Eric Wirtschafter, Christine VanBeek and Yuliya Linhares

    Citation: Experimental Hematology & Oncology 2018 7:14

    Content type: Case report

    Published on:

Submit manuscript

Follow

Annual Journal Metrics

On the blog

Advertisement

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us